A Single-centre, Double-blind, Placebo-controlled, Study in Healthy Men to Assess the Safety and Tolerability of Single and Repeated Ascending Doses of MGB-BP-3
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2016
At a glance
- Drugs MGB BP 3 (Primary)
- Indications Clostridium infections
- Focus Adverse reactions; First in man
- Sponsors MGB Biopharma
- 14 Jun 2016 Data will be presented at the ASM Microbe 2016 meeting, according to a MGB Biopharma media release.
- 14 Jun 2016 Results published in a MGB Biopharma media release.
- 09 May 2016 According to a MGB Biopharma media release, data from this study was presented during a pre-Investigational New Drug (pre-IND) meeting with the Food and Drug Administration (FDA) to discuss the regulatory strategy for the development programme of MGB-BP-3 in the US.